MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Genetic Disease Research

Background:

• Hypertrophic cardiomyopathy (HCM) is a primary inherited cardiac condition and a leading cause of sudden cardiac death in youth.
• HCM arises from mutations in genes responsible for contractile proteins, with MYBPC3 being a key gene.
• Cardiac myosin binding protein-C (cMyBP-C) mutations, especially a specific 25 base pair deletion in MYBPC3, are prevalent and linked to HCM.

Purpose of the Study:

• To review the impact of the cMyBP-C(C10mut) variant on cardiac function.
• To highlight the necessity for developing genetic testing and advanced therapeutic interventions.
• To underscore the importance of understanding C-terminal mutations in HCM pathogenesis.

Main Methods:

• Review of scientific literature on MYBPC3 mutations and hypertrophic cardiomyopathy.
• Analysis of the molecular consequences of the 25 base pair deletion in MYBPC3.
• Discussion of potential research models including induced pluripotent stem cells and mouse models.

Main Results:

• The 25 base pair deletion in MYBPC3 leads to exon 33 skipping and a reading frame shift, producing a truncated cMyBP-C protein (cMyBP-C(C10mut)).
• This mutation is prevalent in South Asian populations, with 4% carrying the variant.
• Carriers exhibit an elevated risk for developing cardiomyopathy and heart failure.

Conclusions:

• The cMyBP-C(C10mut) variant poses a significant risk for HCM and heart failure, necessitating targeted screening in at-risk populations.
• Further research using in vitro and in vivo models is essential to elucidate the functional impact of C-terminal mutations.
• Development of novel therapeutic strategies, including gene repair and gene therapy, is critical to mitigate the clinical effects of this mutation.